This study tests a new way to give blinatumomab, a medicine for a type of blood cancer called Acute Lymphoblastic Leukemia (ALL). It focuses on giving a special kind of chemotherapy, called intrathecal chemotherapy (medicine inserted into the spine), before and during blinatumomab treatment. This aims to protect the brain and nerves from harm caused by a reaction called cytokine release.

• The study is for adults with certain types of ALL who haven't received blinatumomab before.
• Participants must have healthy kidneys and liver, and not have any diseases affecting the brain.
• The study might involve several visits to the research clinic.

If you are eligible, the study team will monitor your health closely to ensure safety. If you have any current infections or other types of cancer, or if you are pregnant, you cannot join this study. The goal is to find out if this new treatment schedule is safe and helps prevent nerve problems while still fighting leukemia effectively.